Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Masahiro Kami"'
Autor:
Tomohiro Morita, Masahiro Kami, Morihito Takita, Tomohiko Sato, Tsunehiko Komatsu, Kana Yamamoto, Wang Na, Suguru Tokiwa, Zhao Gen-ming, Shigeaki Kato, Tetsuya Tanimoto
Publikováno v:
Blood. 132:5890-5890
Introduction: Anemia, one of the most common and widespread disorders in the world, is a public health problem, and among various causes, iron deficiency is the most common cause of anemia, affecting more than 2.2 billion people worldwide. In develop
Autor:
Tetsuya Tanimoto, Naoko Murashige, Yasuo Oshima, Masahiro Kami, Tomoko Matsumura, Akiko Hori, Yuko Kodama
Publikováno v:
Web of Science
Abstract 2572 Backgroud: In Japan, bortezomib (Velcade; Janssen Pharmaceutical Corporation, Tokyo, Japan) was approved on October 2006 for relapsed or refractory multiple myeloma, and sales began on the open market in December 2006. The approval proc
Autor:
Masahiro Kami, Kosei Matsue, Yuji Miura, Naoko Takei, Takehiro Issiki, Yuji Satou, Masaharu Tsubokura, Tsunehiko Komatsu
Publikováno v:
Blood. 112:5215-5215
Background: Deep vein thrombosis (DVT) is an important complication of thalidomide therapy especially when it is combined with corticosteroids or chemotherapy. Japanese patients with multiple myeloma (MM) are currently prescribed thromboprophylaxis a
Autor:
Shuichi Taniguchi, Koichiro Yuji, Makoto Murata, Shunichi Kato, Yuko Osugi, Takuhiro Yamaguchi, Yasushi Kouzai, Koji Kato, Ryuji Kobayashi, Morihito Takita, Masami Inoue, Masahiro Kami, Tomoko Matsumura, Tokiko Nagamura, Satoshi Takahashi, Masaya Okada, Shunro Kai, Hisashi Sakamaki
Publikováno v:
Blood. 110:2026-2026
Unrelated cord blood transplantation (u-CBT) may provide a treatment option for patients with malignant lymphoma (ML) who have failed other conventional therapies and do not have a compatible donor available. Japan Cord Blood Bank Network (JCBNW) has
Autor:
Tsunehiko Komatsu, Shosaku Nomura, Takayuki Takubo, Atsuko Mugitani, Nobuhiko Uoshima, Kunio Hayashi, Toshio Shimokawa, Masahiro Kami, Minoru Hasegawa, Tamae Hamaki
Publikováno v:
Blood. 110:4756-4756
Introduction: Bone disease in patients with myeloma is the devastating complication. RANTES (CCR chemokine, Regulated upon Activation,Normal T Cell Expressed and Secreted) is involved in the bone remodeling that is made by coupled functions of osteoc
Autor:
Shigesaburo Miyakoshi, Tokiko Nagamura, Shunichi Kato, Masahiro Kami, Tomoko Matsumura, Hiroto Narimatsu, Yasushi Kouzai, Koichiro Yuji, Satoshi Takahashi, Shunro Kai, Makoto Murata, Hisashi Sakamaki, Takuhiro Yamaguchi, Shuichi Taniguchi, Yuko Osugi, Eiji Kusumi, Koji Kato, Masaya Okada, Masami Inoue, Ryuji Kobayashi
Publikováno v:
Blood. 110:1070-1070
BACKGROUND Limited information is available on incidences and clinical features of acute graft-versus host disease (GVHD) after cord blood transplantation and large-sized researches have been awaited. METHODS We investigated the incidences and clinic
Autor:
Tomoko Matsumura, Yoshinobu Kanda, Yuko Kodama, Rikako Koyama, Tsunehiko Komatsu, Masahiro Kami, Shuichi Taniguchi, Masayo Fujiwara, Shigesaburo Miyakoshi, Kunihiko Seki, Koichiro Yuji, Eiji Kusumi
Publikováno v:
Blood. 108:5322-5322
Liver injury is a common complication in allogeneic hematopoietic stem cell transplantation. Its major causes comprise graft-versus-host disease (GVHD), infection, and toxicities of preparative regimens and immunosuppressants; however, we have little
Autor:
Hirohisa Nakamae, Kinuko Tajima, Kazuo Hatanaka, Sung-Won Kim, Ryuji Tanosaki, Kazutaka Sunami, Shinichiro Mori, Mine Harada, Kazunori Nakase, Takahiro Fukuda, Chihiro Shimazaki, Toshiro Ito, Masayuki Hino, Makoto Hirokawa, Toshiharu Tamaki, Yasukazu Kawai, Chisato Mizutani, Yoichi Takaue, Shuichi Taniguchi, Koji Nagafuji, Masahiro Kami, Yasunori Ueda
Publikováno v:
Blood. 108:5397-5397
[Background] We report the results of a prospective multi-institutional clinical trial of BMT from an HLA-matched URD following RIC. [Patients and Methods] The conditioning regimen included cladribine 0.11 mg/kg on day -8 to day -3, busulfan 4 mg/kg
Autor:
Keitaro Matsuo, Tamae Hamaki, Masahiro Kami, Kengo Takeuchi, Ritsuro Suzuki, Yukiko Kishi, Shigeo Nakamura, Yuji Tanaka, Hiroto Narimatsu, Yasunori Ota
Publikováno v:
Blood. 108:2445-2445
Pyothorax-associated lymphoma (PAL) is a lymphoproliferative disorder developing in the pleural cavity after a long-standing history of pyothorax. The pathogenesis, clinical features and optimal treatment have not been clarified. To investigate clini
Autor:
Mari Kannagi, Jun Okamura, Sung-Won Kim, Shunro Sonoda, Takahiro Fukuda, Kisato Nosaka, Ryuji Tanosaki, Masahiro Kami, Shinichiro Mori, Kensei Tobinai, Yoichi Takaue, Shin Mineishi
Publikováno v:
Blood. 106:3347-3347
Background. ATL is an HTLV-I-associated hematological malignancy. The majority of ATL patients are not curable using current chemotherapy with median survival time of 13 months. Recently, patients undergoing allo-SCT with conventional conditioning re